Early cancer detection and screening at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

15 organizations at ISLB 2026 present work in early detection & screening: 5 diagnostics companies, 4 universities and research institutes, 4 hospitals and 2 suppliers and service providers. Between them they bring 31 presentations to the program. Most represented: University of Minnesota, Mayo Clinic and Guardant Health. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–13 of 15 organizations

Organization	ISLB 2026 Attendance
University of Minnesota Minneapolis, MN
umn.edu Universities & research institutes Public research university in Minneapolis and Saint Paul, Minnesota, with medical and veterinary schools.	Poster Part of Poster sessions Single-cell Profiling of Liquid Biopsy Cells Associated with Cancer Risk Reveals Increased Inferred Copy Number Variation Early detection · New analytes Poster Part of Poster sessions Integration of the Shine on Suspicion Test and eBAT Interventional Therapy for Canine Cancer Prevention Early detection Poster Part of Poster sessions Disentangling Biological Signal from Technical Noise in Multi-matrix Cell-free DNA Profiling of Canine Diffuse Large B-cell Lymphoma Pre-analytics · ctDNA & MRD Poster Part of Poster sessions Test and Intervene: a Strategic Framework for Liquid Biopsy-guided Cancer Prevention Early detection
Mayo Clinic Rochester, MN
mayoclinic.org Hospitals & cancer centres Non-profit academic medical center with campuses in Minnesota, Arizona and Florida, providing patient care, research and education.	Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures Non-invasive Profiling of the Tumor Microenvironment with Spatial Ecotypes New analytes Poster Part of Poster sessions Therapeutic Plasma Exchange as a Window into cfDNA Kinetics ctDNA & MRD Poster Part of Poster sessions Family-resolved Methylation Uncovers Cancer Signal Hidden in Plasma Cell-free DNA Repetitive Elements Early detection · ctDNA & MRD
Guardant Health Palo Alto, CA	◆Gold Sponsor
guardanthealth.com Diagnostics & testing labsGold Sponsor Blood and tissue cancer tests for screening, recurrence monitoring and treatment selection, plus real-world data and analytics for drug developers.	Booth Exhibiting at Booth 2 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Industry Mon Nov 9 8:00am–9:00am From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Clinical use · ctDNA & MRD Poster Part of Poster sessions HLA and Pharmacogenomics Typing Concordance Between Buffy Coat Sequencing and a Plasma-based Liquid Biopsy Assay New analytes · Pre-analytics
ASST Papa Giovanni XXIII Bergamo, Italy
asst-pg23.it Hospitals & cancer centres Public hospital trust in Bergamo running the Papa Giovanni XXIII hospital.	Poster Part of Poster sessions Longitudinal ctDNA Methylation Profiling Reveals Treatment Response and Persistent Molecular Disease in Peripheral T-Cell Lymphoma ctDNA & MRD Collaborators: Humanitas Research Hospital Poster Part of Poster sessions Targeted Cell-free DNA Methylation Profiling Discriminates Breast-cancer Cases from Healthy Controls and Tracks Clinical and Molecular Features Early detection · ctDNA & MRD Collaborators: Humanitas Research Hospital
Flomics Biotech Barcelona, Spain
flomics.com Diagnostics & testing labs Develops a cell-free RNA blood test for early cancer detection using sequencing and machine learning, and offers RNA sequencing and bioinformatics services.	Poster Part of Poster sessions A Robust Cell-free RNA Approach for the Early Detection of Colorectal Cancer Early detection · New analytes Poster Part of Poster sessions Cell-free RNA in Precision Medicine: Unlocking New Clinical Insights with ARdeNA New analytes Collaborators: Hospital Sant Joan de Déu Barcelona, University of Valencia
Hospital Clínic de Barcelona Barcelona, Spain
clinicbarcelona.org Hospitals & cancer centres University hospital in Barcelona, linked to the IDIBAPS research institute.	Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related Melanoma and Liquid Biopsy Including Fragmentomics Clinical use Poster Part of Poster sessions Inferring Cell-type Signatures from cfDNA Fragmentation Profiles in Melanoma and Benign Melanocytic Lesions ctDNA & MRD · Early detection
McGill University Health Centre Montreal, Canada
muhc.ca Hospitals & cancer centres Academic health network of McGill University's teaching hospitals in Montreal, with its own research institute.	Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session From Molecular Discovery to Clinical Implementation: Longitudinal ctDNA Profiling Defines Molecular Residual Disease and Informs the MONITOR De-escalation Trial Collaborators: McGill University Poster Part of Poster sessions Evaluating Liquid Biopsy for Circulating Tumor DNA Detection as a Complementary Diagnostic Tool in Thyroid Nodules Early detection · ctDNA & MRD Collaborators: McGill University
biomodal Cambridge, United Kingdom
biomodal.com Sequencing, instruments & reagents Sequencing chemistry and analysis that read DNA methylation and hydroxymethylation alongside the genetic sequence, applied to cfDNA.	Poster Part of Poster sessions Integrated 6-base cfDNA Profiling Reveals Complementary Genetic, Epigenetic and Fragmentomic Biomarkers, Enabling Optimal Biomarker Combinations for Cancer Detection Early detection · ctDNA & MRD Poster Part of Poster sessions Fragment-level Integration of Epigenetic and Genetic Signals for Ultra-sensitive ctDNA Detection in Liquid Biopsy and MRD Applications ctDNA & MRD Poster Part of Poster sessions Removal of End-repair Reduces Hypomethylation Artefacts and Improves ctDNA Detection and Tissue-of-origin Determination in cfDNA Assays ctDNA & MRD · New analytes
Health Research Institute Hospital La Fe (IIS La Fe) Valencia, Spain
iislafe.es Universities & research institutes Health research institute of La Fe University Hospital in Valencia.	Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Peritoneal Fluid Reveals a NETosis-associated Cytokine Signature with Diagnostic and Prognostic Value in Advanced High-grade Serous Ovarian Cancer Collaborators: University of Valencia Poster Part of Poster sessions Plasma Lipidomics Links Bladder Cancer Progression to NETosis, Reduced Active DnaseI, and Thrombin Formation New analytes Poster Part of Poster sessions Integrated Analysis of Circulating Mirnas in Plasma and Peritoneal Fluid Identifies a Diagnostic Signature for High-grade Serous Ovarian Cancer New analytes · Early detection Collaborators: University of Valencia
University of Wisconsin–Madison Madison, WI
wisc.edu Universities & research institutes Public research university in Madison, Wisconsin, with medical and veterinary schools.	Talk Sun Nov 8 3:00pm–3:45pm Part of Poster Tour Feasibility of Extracellular Vesicle and Single-cell Transcriptomic Profiling of Synovial Fluid in Canine Immune-mediated Polyarthritis and Osteoarthritis Collaborators: University of Minnesota Poster Part of Poster sessions Extracellular Vesicle mRNA Profiling for Prognostic Biomarker Discovery in Pediatric Osteosarcoma: the KIDsCAN Study New analytes · Clinical use Collaborators: University of Minnesota Poster Part of Poster sessions Early Detection and Risk Assessment of Canine Osteosarcoma: Preliminary Results of the Canine Osteosarcoma Early Detection Study Early detection Collaborators: University of Minnesota
GenoME Diagnostics Belfast, United Kingdom
genomediagnostics.co.uk Diagnostics & testing labs Queen's University Belfast spinout developing blood tests that read DNA methylation and fragmentation, for ovarian cancer monitoring and pancreatic cancer detection.	Talk Sun Nov 8 3:00pm–3:45pm Part of Poster Tour Development of A Novel Digital PCR Multiplex Test for Improved Ovarian Cancer Disease Monitoring. Poster Part of Poster sessions Development of Novel Liquid Biopsy for the Improved Diagnosis of Pancreatic Cancers. Early detection
Cogentech Milan, Italy
cogentech.it Diagnostics & testing labs Genetic testing laboratory for hereditary cancers that also provides sequencing, proteomics and pathology research services; part of the IFOM cancer research foundation.	Poster Part of Poster sessions Development and Validation of a DNA Methylation Signature for Detection of Hereditary Breast Cancer Using Tissue and Liquid Biopsy Samples Early detection
IdiPAZ Madrid, Spain
idipaz.es Universities & research institutes Health research institute of La Paz University Hospital in Madrid.	Poster Part of Poster sessions Poly Functional Immune Liquid Biopsy (PolyFIL) in Blood for the Differential Diagnosis of Colorectal Adenomas and Cancer Early detection · New analytes